Dorothy Graves was named assistant vice president and associate director for administration of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.
Davey Daniel was appointed chief medical officer of OneOncology on Feb. 7, succeeding Lee Schwartzberg, who will remain a senior advisor to the company.
The NCI-MATCH trial offers treatment opportunities for adult patients with relapsed, refractory cancers. A new treatment arm (Z1M) is evaluating the immunotherapy combination of relatlimab and nivolumab in patients whose tumors have mismatch repair deficiency and LAG-3 expression and have progressed after anti–PD-1/PD-L1 immunotherapy.
A study suggests that the malaria drug hydroxychloroquine inhibits pathways that drive resistance to the chemotherapy agent cisplatin in head and neck cancers and restores tumor-killing effects of cisplatin in animal models.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) conducted an extensive review of both peer-reviewed research studies and governmental public health data, looking at the so-called “intersectionality” of factors influencing health disparities to determine that sexual and racial minority status influences cancer screening behaviors and cancer risk.
Yale Cancer Center researchers have identified novel oncogenic gene fusions in lung and pancreatic cancer, as well as sarcoma. The fusions involve RASGRF1 (an activator of RAS signaling) and promote cellular changes leading to tumor development.
Scientists at Yale Cancer Center have discovered consequences of specific gene mutations that play a role in the development of myelodysplastic syndromes and acute myeloid leukemia.
A study out of Ontario, Canada found an immediate cancer diagnosis decrease of 34% in March 2020, followed by a slow and incomplete recovery.
FDA has approved for FoundationOne CDx to be used as a companion diagnostic to identify patients with non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) alterations and are appropriate for treatment with EGFR tyrosine kinase inhibitors approved by FDA for this indication.
Strata Oncology Inc. announced enrollment of the first patient in the Strata Sentinel trial, a prospective, observational study that will evaluate the ability of the investigational StrataMRD test to detect cancer recurrence in advance of standard of care techniques across solid tumors, as well as the clinical benefit of treatment in early-stage patients who are or become ctDNA-positive after surgery or other therapy with curative intent.
